PT  - JOURNAL ARTICLE
AU  - Jamal, Mohammad H.
AU  - Doi, Suhail A.
AU  - AlYouha, Sarah
AU  - Almazeedi, Sulaiman
AU  - Al-Haddad, Mohannad
AU  - Al-Muhaini, Ali
AU  - Al-Ghimlas, Fahad
AU  - Al-Sabah, Salman
TI  - Predicting Disease Progression in COVID19: A Score Based On Lab Tests At Time Of Diagnosis
AID  - 10.1101/2020.05.05.20088906
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.05.20088906
4099  - http://medrxiv.org/content/early/2020/05/09/2020.05.05.20088906.short
4100  - http://medrxiv.org/content/early/2020/05/09/2020.05.05.20088906.full
AB  - Background COVID19 is worldwide pandemic that is mild in the majority of patients but can result in a pneumonia like illness with progression to acute respiratory distress syndrome and death. Predicting the disease severity at time of diagnosis can be helpful in prioritizing hospital admission and resources.Methods We prospectively recruited 1096 consecutive patients with COVID19 from the Jaber Hospital, a COVID19 facility in Kuwait, between 24 February and 20 April 2020. The primary endpoint of interest was disease severity defined algorithmically. Predefined risk variables were collected at the time of PCR based diagnosis of the infection. Prognostic model development used 5-fold cross-validated regularized logit regression. The cohort was divided into a training and validation cohort and all model development proceeded on the training cohort.Results There were 643 patients with clinical course data of whom 94 developed severe COVID19. In the final model, age, CRP, procalcitonin, lymphocyte and monocyte percentages and serum albumin were independent predictors of a more severe illness course. The final prognostic model demonstrated good discrimination, calibration and internal validity.Conclusion We developed and validated a simple score calculated at time of diagnosis that can predict patients with severe COVID19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding obtainedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA